readthroughSign in
Nov 16, 2026Quarterly update

Galectin submits Phase 3 protocol for belapectin after FDA alignment on trial design

The MASH cirrhosis drug developer filed its registrational trial protocol in the third quarter of 2026 and reported $11.7 million in cash as of September 30, 2026.

Galectin Therapeutics said on November 16, 2026 that it filed a registrational Phase 3 trial protocol for belapectin with the FDA during the third quarter of 2026, following agency alignment on key elements of the planned trial design, including a primary endpoint of composite liver outcome, a blinded central review process for endoscopic assessment of esophageal varices, and use of a single 2 mg/kg LBM dose of belapectin.1 The company said additional information is expected at its Annual Stockholders' Meeting on December 3, 2026.1

Belapectin, described as a complex carbohydrate drug that targets galectin-3, a protein implicated in the pathogenesis of MASH and fibrosis1, was also the subject of new data presented at the AASLD Annual Meeting in Denver. In an oral presentation, belapectin treatment was associated with a favorable shift toward lower ANTICIPATE-NASH predicted clinically significant portal hypertension risk at 18 months, with a net 15.9% placebo-adjusted improvement (p=0.04)1, from the NAVIGATE trial. The company said the findings suggest belapectin may reduce CSPH risk and potentially future hepatic decompensation.1

On the balance sheet, Chairman Richard E. Uihlein converted all outstanding principal and accrued interest under five of the company's line of credit facilities into common stock, effective July 31, 20261, eliminating approximately $105.8 million in total debt, consisting of $91.0 million in principal and $14.8 million in accrued interest1, in exchange for issuance of 34,376,167 shares of common stock to Mr. Uihlein.1

As of September 30, 2026, Galectin had $11.7 million of cash and cash equivalents1, plus $10 million remaining available under a line of credit provided by its Chairman of the Board.1 The company said it believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027.1

For the quarter ended September 30, 2026, Galectin reported a net loss applicable to common stockholders of $3.6 million, or $(0.04) per share, compared with a net loss applicable to common stockholders of $8.2 million, or $(0.13) per share, for the quarter ended June 30, 20251, the comparison period the company specified in its release.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.